List of Yutiq drug patents
Yutiq is owned by Eyepoint Pharms.
Yutiq contains Fluocinolone Acetonide.
Yutiq has a total of 2 drug patents out of which 0 drug patents have expired.
Yutiq was authorised for market use on 12 October, 2018.
Yutiq is available in implant;intravitreal dosage forms.
Yutiq can be used as a method of injecting an implant.
The generics of Yutiq are possible to be released after 12 January, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871241 | EYEPOINT PHARMS | Injectable sustained release delivery devices |
Aug, 2027
(4 years from now) | |
| US7998108 | EYEPOINT PHARMS | Injector apparatus and method of use |
Jan, 2028
(4 years from now) | |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 12 October, 2018
Treatment: A method of injecting an implant
Dosage: IMPLANT;INTRAVITREAL
YUTIQ family patents
52
United States
13
Japan
12
China
12
European Union
11
Australia
9
Canada
9
Taiwan
7
Spain
7
Denmark
7
Argentina
7
Slovenia
6
Austria
6
Korea, Republic of
6
Mexico
5
Germany
5
Brazil
5
New Zealand
4
Cyprus
4
Portugal
3
Poland
2
Hong Kong
2
Israel
2
South Africa
1
Malaysia
1
India
1
EA
1
Norway
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic